血IL-6水平作为阿尔茨海默病行为变化的生物标志物
Neuroimmunomodulation
|August 18, 2025
概括
周围的IL-6水平与阿尔茨海默病 (AD) 的行为症状有关,这与大脑炎症无关. 这表明IL-6是AD相关行为障碍的潜在生物标志物和治疗标.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 老年学是一门学科.
背景情况:
- 痴呆症的行为和心理症状 (BPSD) 显著影响阿尔茨海默病 (AD) 患者的生活质量和护理人员负担.
- 系统性炎症与阿尔茨海默病有关,但在BPSD中外周免疫活性,特别是IL-6的作用尚不清楚,特别是它与中央神经炎症的独立性.
研究的目的:
- 调查外周和中心炎症标志物之间的关联以及阿尔茨海默病患者BPSD的严重程度.
- 为了确定外围IL-6水平是否可以预测BPSD严重程度,而不依赖于神经炎症.
主要方法:
- 对23名生物标志物确诊的AD或预发性AD患者的横截面研究.
- 测量了IL-6,IL-1β,TNF-α和C反应蛋白 (CRP) 的血和脑脊液 (CSF) 水平.
- 通过11C-DPA-713 TSPO-PET评估BPSD使用痴呆行为障碍 (DBD) 尺度和中央神经炎症;使用回归和贝叶斯方法分析数据.
主要成果:
- 在频率主义和贝叶斯分析中,血IL-6是DBD得分的唯一显著预测因子.
- 脑流体IL-6,其他炎症标志物和TSPO-PET结合与行为症状没有相关性.
- 血和CSFIL-6水平之间或血IL-6和TSPO-PET测量之间没有发现相关性.
结论:
- 外周IL-6与AD中的BPSD严重程度显著相关,独立于中心炎症标志物.
- 表明在阿尔茨海默氏症中神经精神病症状有明显的外周免疫机制,可能是通过全身途径.
- 周围IL-6可能代表AD行为障碍的临床相关生物标志物和治疗标.
更多相关视频
07:28Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
4.0K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.9K
相关概念视频
Alzheimer's Disease: Overview
668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668
Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261
